Topiramate-induced modulation of hepatic molecular mechanisms: An aspect for its Anti-Insulin resistant effect

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  El Abhar, Hanan S ^a   Schaalan, Mona F ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b Egypt   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN RECEPTOR; ALANINE AMINOTRANSFERASE; GLUCOSE TRANSPORTER 2; INSULIN RECEPTOR; PROTEIN TYROSINE KINASE; TOPIRAMATE; TUMOR NECROSIS FACTOR ALPHA; DRUG DERIVATIVE; FRUCTOSE; SLC2A2 PROTEIN, RAT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARBOHYDRATE DIET; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; EPIDIDYMAL FAT WEIGHT; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID ANALYSIS; LIPID DIET; LIPID METABOLISM; LIVER WEIGHT; MALE; MOLECULAR MECHANICS; NONHUMAN; PROTEIN INDUCTION; RAT; RECEPTOR UPREGULATION; VISCERAL FAT WEIGHT; WEIGHT; ANALYSIS OF VARIANCE; ANIMAL; DRUG EFFECT; GLUCOSE TOLERANCE TEST; INTRAABDOMINAL FAT; LIVER; METABOLISM; ORGAN SIZE; PHYSIOLOGY; WISTAR RAT;

ANIMALIA; RATTUS NORVEGICUS;

ANALYSIS OF VARIANCE; ANIMALS; DIET, HIGH-FAT; FRUCTOSE; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORTER TYPE 2; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIVER; MALE; ORGAN SIZE; PROTEIN-TYROSINE KINASES; RATS; RATS, WISTAR; RECEPTORS, ADIPONECTIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861397073     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037757     Document Type: Article

References (61)

1. Amin KA, Nagy MA, (2009) Effect of carnitine and herbal mixture extract on obesity induced by high fat diet in rats. Diabetol Metab Synd 17: 1-14.
2. Lonardo A, Lombardini S, Ricchi M, Scaglioni F, Loria P, (2005) Review article: hepatic steatosis and insulin resistance. Aliment Pharmacol Ther 22: 64-70.
3. Roden M, (2006) Mechanisms of Disease: hepatic steatosis in type 2 diabetes-pathogenesis and clinical relevance. Nat Clin Pract Endocrinol Metab 2: 335-348 Review.
4. Miyazaki Y, Mahankali A, Matsuda M, (2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type-2 diabetic patients. J Clin Endocrinol Metab 87: 2784-2791.
5. Tsuchida A, Yamauchi T, Takekawa S, (2005) Peroxisome proliferator-activated receptor (PPAR)-α activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue comparison of activation of PPARα, PPARγ, and their combination. Diabetes 54: 3358-3370.
6. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, et al. (2001) The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7: 941-946.
7. Basciano H, Federico L, Adeli K, (2005) Fructose, insulin resistance, and metabolic dyslipidemia. Nutr Metab 2: 1-5.
8. Moore MC, Cherrington AD, Mann SL, Davis SN, (2000) Acute fructose administration decreases the glycemic response to an oral glucose tolerance test in normal adults. J Clin Endocrinol Metab 85: 4515-4519.
9. De Fronzo RA, (1997) Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5: 177-269.
10. Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y, (2000) Influences of Topiramate in the regulation of energy balance. Nutrition 16: 961-966.
11. Wilkes JJ, Audrey Nguyen MT, Bandyopadhyay GK, Nelson E, Olefsky JM, (2005a) Topiramate treatment causes skeletal muscle insulin sensitization and increased Acrp30 secretion in high-fat-fed male Wistar rats. Am J Physiol Endocrinol Metab 289: E1015-E1022.
12. Huang BW, Chiang MT, Yao HT, Chiang W, (2004) The effect of high-fat and high-fructose diets on glucose tolerance and plasma lipid and leptin levels in rats. Diabetes ObesMetab 6: 120-126.
13. Psyrogiannis A, Kyriazopoulou V, Symeonidis A, (2003) Relative iron 'overload' in offspring of patients with type 2 diabetes mellitus: a new component in the conundrum of insulin resistance syndrome? Hormones 2: 161-168.
14. Wang P, Ren RN, Cai SY, Chen XM, Ye LY, (2008) Neuroprotective effects of topiramate and folic acid on young rats with kindling-induced epilepsy. Zhongguo Dang Dai Er Ke Za Zhi 10: 65-69 [Abstract].
15. Wilkes JJ, Nelson E, Osborne M, Demarest KT, Olefsky JM, (2005b) Topiramate is an insulin-sensitizing compound in vivo with direct effects on adipocytes in female ZDF rats. Am J Physiol Endocrinol Metab 288: E617-E624.
16. Barham D, Trinder P, (1972) An improved colour reagent for the determination of blood glucose by the oxidase system. Analyst 97: 142-145.
17. Schleicher ED, Vogt BW, (1990) Standardization of serum fructosamine assays. Clin Chem 36: 136-139.
18. Nagele U, Hagele EO, Sauer G, Wiedemann E, Lehmann P, et al. (1984) Reagent for the enzymatic determination of serum total triglycerides with improved lipolytic efficiency. J Clin Chem Clin Bio 22: 165-174.
19. Fasce CF, (1982) Enzymatic colorimetric method determination of total cholesterol in human serum. Clin Chem 28: 901-907.
20. González-Sánchez JL, Zabena CA, Martínez-Larrad MT, Fernández-Pérez C, Pérez-Barba M, et al. (2005) An SNP in the adiponectin gene is associated with decreased serum adiponectin levels and risk for impaired glucose tolerance. Obes Res 13: 807-812.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and μ-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
22. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
23. Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz-Schughart LA, et al. (2006) Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. J Mol Endocrinol 36: 485-501.
24. Schütt M, Brinkhoff J, Drenckhan M, Lehnert H, Sommer C, (2010) Weight reducing and metabolic effects of topiramate in patients with migraine-an observational study. Exp Clin Endocrinol Diabetes 118: 449-452.
25. Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, et al. (1985) Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313: 756-761.
26. Sesti G, Federici M, Lauro D, Sbraccia P, Lauro R, (2001) Molecular mechanism of insulin resistance in type 2 diabetes mellitus: role of the insulin receptor variant forms. Diabetes Metab Res Rev 17: 363-373.
27. Mosthab L, Vogt B, Haring HU, Ullrich A, (1991) Altered expression of insulin receptor types A and B in the skeletal muscle of noninsulin-dependent diabetes mellitus. Proc Natl Acad Sci U S A 88: 4728-4730.
28. Keller M, Sesti G, Seffer E, Obermaier-Kusser B, Pongratz DE, et al. (1993) Altered pattern of insulin receptor isotypes in skeletal muscle membranes of type II (noninsulin-dependent) diabetic subjects. Diabetologia 36: 628-632.
29. Sesti G, Marini MA, Tullio AN, Montemurro A, Borboni P, et al. (1991) Altered expression of the two naturally occurring human insulin receptor variants in isolated adipocytes of non-insulin-dependent diabetes mellitus patients. Biochem Biophys Res Commun 181: 1419-1424.
30. Sbraccia P, D'Adamo M, Leonetti F, Caiola S, Iozzo P, et al. (1996) Chronic primary hyperinsulinemia is associated with altered insulin receptor mRNA splicing in muscle of patients with insulinoma. Diabetologia 39: 220-225.
31. Grunberger G, Zick Y, Gordon P, (1984) Defect in phosphorylation of insulin receptors in cells from an insulin-resistant patient with normal insulin binding. Science 223: 932-934.
32. Caro JF, Ittoop O, Pories WJ, Meelheim D, Flickinger EG, et al. (1986) Studies on the mechanism of insulin resistance in the liver from humans with noninsulin-dependent diabetes. Insulin action and binding in isolated hepatocytes, insulin receptor structure, and kinase activity. J Clin Invest 78: 249-258.
33. Arner P, Pollare T, Lithell H, Livingston JN, (1987) Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30: 437-440.
34. Burcelin R, Eddouks M, Kande J, Assan R, Girard J, (1992) Evidence that GLUT-2 mRNA and protein concentrations are decreased by hyperinsulinaemia and increased by hyperglycaemia in liver of diabetic rats. Biochem J 288: 675-679.
35. Postic C, Burcelin R, Rencurel F, Pegorier JP, Loizeau M, (1993) Evidence for a transient inhibitory effect of insulin on GLUT2expression in the liver: studies in vivo and in vitro. Biochem J 293: 119-124.
36. Rencurel F, Waeber G, Antoine B, Rocchiccioli F, Maulard P, (1996) Requirement of glucose metabolism for regulation of glucose transporter type 2 (GLUT2) gene expression in liver. Biochem J 314: 903-909.
37. Granner DK, Pilkis S, (1990) The Genes of Hepatic Glucose Metabolism. J Biol Chem 265: 10173-10176.
38. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, et al. (2004) Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279: 32345-32353.
39. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, et al. (2005) Adiponectin and its receptors in non-alcoholic steato-hepatitis. Gut 54: 117-121.
40. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, et al. (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyper-insulinemia. J Clin Endocrinol Metab 86: 1930-1935.
41. Lu JY, Huang KC, Chang LC, Huang YS, Chi YC, et al. (2008) Adiponectin: a biomarker of obesity-induced insulin resistance in adipose tissue and beyond. J Biomed Sci 15: 565-576 Review.
42. Milan G, Granzotto M, Scarda A, Calcagno A, Pagano C, et al. (2002) Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss. Obes Res 10: 1095-1103.
43. Kadowaki T, Yamauchi T, (2005) Adiponectin and Adiponectin Receptors. Endocrine Reviews 26: 439-451.
44. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, et al. (2007) Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13: 332-339.
45. Iwaki M, Matsuda M, Maeda N, Funahashi T, Matsuzawa Y, et al. (2003) Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52: 1655-1663.
46. Gustafson B, Jack MM, Cushman SW, Smith U, (2003) Adiponectin gene activation by thiazolidinediones requires PPAR gamma 2, but not C/EBP alpha-evidence for differential regulation of the aP2 and adiponectin genes. Biochem Biophys Res Commun 308: 933-939.
47. Nguyen SA, Malcolm R, Middaugh LD, (2007) Topiramate reduces ethanol consumption by C57BL/6 mice. Synapse 6: 150-156.
48. Czyzyk TA, Sahr AE, Statnick MA, (2010) A model of binge-like eating behavior in mice that does not require food deprivation or stress. Obesity (Silver Spring) 18: 1710-1717.
49. York DA, Singer L, Thomas S, Bray GA, (2000) Effect of topiramate on body weight and body composition of Osborne-Mendel rats fed a high-fat diet: alterations in hormones, neuropeptides, and uncoupling- protein mRNAs. Nutrition 16: 967-975.
50. Abo-Elmatty DM, Zaitone SA, (2011) Topiramate induces weight loss and improves insulin sensitivity in dietary obese rats: comparison to sibutramine.Eur Rev Med Pharmacol Sci. 15 (10): 1187-95.
51. Tonstad S, Tykarski A, Weissgarten J, Ivleva A, Levy B, et al. (2005) Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol 35: 243-251.
52. Miyazaki Y, Mahankali A, Matsuda M, (2002) Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type-2 diabetic patients. Clinl Endocrino Metabol 87: 2784-2791.
53. Tsuchida A, Yamauchi T, Takekawa S, (2005) Peroxisome proliferator-activated receptor (PPAR)-α activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue comparison of activation of PPARα, PPARγ, and their combination. Diabetes 54: 3358-3370.
54. Liang H, Yin B, Zhang H, Zhang S, Zeng Q, et al. (2008) Blockade of tumor necrosis factor (TNF) receptor type 1-mediated TNF signaling protected Wistar rats from diet-induced obesity and insulin resistance. Endocrinology 149: 2943-2951.
55. Vozarova B, Stefan N, Lindsay RS, (2002) High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type-2 diabetes. Diabetes 51: 1889-1895.
56. O'Brien RM, Granner DK, (1991) Regulation of gene expression by insulin. Biochem J 278: 609-619.
57. Liang Y, She P, Wang X, Demarest K, (2006) The messenger RNA profiles in liver, hypothalamus, white adipose tissue, and skeletal muscle of female Zucker diabetic fatty rats after topiramate treatment. Metabolism 55: 1411-1419.
58. Frigerio F, Chaffard G, Berwaer M, Maechle P, (2006) The antiepileptic drug topiramate preserves metabolism-secretion coupling in insulin secreting cells chronically exposed to the fatty acid oleate. Biochem Pharmacol 72: 965-973.
59. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U, (2003) Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 11: 556-562.
60. Koçer A, Dikici S, Atakay S, Okuyucu S, (2008) Serum uric acid and lipid levels while taking topiramate for migraine. Headache 48: 1056-1060.
61. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, et al. (2008) Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment. US Multisite Randomized Controlled Trial. Arch Intern Med 168: 1188-1199.